LaunchBio Inc.’s Post

🌟 Exciting News in Biotech! 🧬 Thrilled to share that veteran biotech entrepreneur Harvey Berger is making a dynamic comeback, taking the helm as CEO at Boston-based startup Kojin Therapeutics! 🚀 🔬 Kojin, founded in 2019, is on a mission to revolutionize treatment with innovative pills leveraging ferroptosis biology. With a scientific team, including Harvard research professor Stuart Schreiber, the company is at the forefront of understanding the role of ferroptosis in various diseases. 🤯🧪 💊 What sets Kojin apart? They're developing two distinct classes of pills - one to induce ferroptosis, targeting cancer cells, and another to block ferroptosis, preventing neurodegenerative diseases. The potential impact on disease treatment is groundbreaking! 🌐💡 🌍 With approximately 15 brilliant minds in their Seaport district hub, Kojin Therapeutics is gearing up to unveil lead drug candidates that could reshape the landscape of biopharmaceuticals. Stay tuned for more updates on this promising venture! 🚀🔍 #BiotechInnovation #Entrepreneurship #Biopharma #InnovativeTherapeutics #KojinTherapeutics #FerroptosisBiology 🧬🌟

Start-ups remain true drivers of #innovation in #Switzerland. They contribute both directly and indirectly to the present and future prosperity. In the past 13 years almost 18,000 new jobs have been created by #deeptech #startups within Switzerland. 📌 Every year, a ranking of the most promising young #Swiss #entrepreneurial #endeavours offers an insight into the current state of the start-up community.  HAYA Therapeutics took the crown as the #winner of this year’s #TOP #100 #Swiss #Startup #Ranking and received the #prestigious #award during show on Wednesday, 6 September 2023 in #Zurich. The Lausanne-based #biotech #company is developing a drug to treat #cardiac #fibrosis caused by #cardiovascular #diseases, which is currently incurable. 🏆 For more details 👇🏻 #Switzerland #Swiss #startup #biotech #medicine #treatment #ranking #award #winner

Great article discussing the recent £17.9 million boost for the UK's Advanced Therapy Treatment Centre network. It's an interesting read on how innovation and entrepreneurship are driving healthcare forward. Have a read: https://lnkd.in/eCqEGt5x Advanced Therapies #CGT #ATTCnetwork #startups

Wow. Groundbreaking scientific discoveries are happening right here in California, and you must check out the latest advancements by CA-based biotech companies. These trailblazers are transforming the landscape of healthcare, life science and industries alike! 🧬 Introducting our article "Spotlight on California Biotech Startups: Pioneers in Revolutionary Innovations" that shares the compelling stories of these exciting startups. Let it inspire you. 👇 https://lnkd.in/d_TKXKhP ☀️ Spotlight on: 1. Resilience - Founded by Drew Oetting, and Rahul Singhvi 2. ACELYRIN, INC. - Founded by Robert Carey, and Shao-Lee Lin, MD, PhD 3. Onc.AI - Founded by Akshay Nanduri, and Salmaan Ahmed 4. Graphite Bio - Founded by Daniel Dever, Maria Grazia Roncarolo, Matthew Porteus 5. Revelation Biosciences Inc. - Founded by Chester S. Zygmont, III 6. Perceive Biotherapeutics, Inc. 7. Longboard Pharmaceuticals - Founded by Kevin R. Lind 8. Shoreline Biosciences, Inc. - Founded by Dan S. Kaufman, Kleanthis G. Xanthopoulos, Marios Fotiadis, Steven Holtzman 9. Cellanome - Founded by Mostafa Ronaghi 10. Pardes Biosciences - Founded by Uri Lopatin, MD 11. Sonoma Biotherapeutics - Founded by Alexander Rudensky, Fred Ramsdell, Jeffrey Bluestone, Qizhi Tang Get to know their amazing work, their innovative solutions, and how they are gearing up to own the future. #biotech #startups #innovation #California #healthcare #lifesciences #revolutionary #pioneers

We are thrilled to announce the addition of Helmuth van Es to our Board! Leiden, The Netherlands, April 8, 2024. Cantoni announced its Board of Directors has been strengthened with biotech industry veteran Helmuth van Es Ph.D. Helmuth van Es has more than 30 years of experience in life sciences as an entrepreneurial scientist and C-suite biotech executive. He was a co-founder of Galapagos and four other therapeutic biotech companies, three of which are at clinical stage and was the former CEO of Citryll developing the NETosis inhibitor to clinical proof of concept stage. A total of €125M was raised into these four startups. Helmuth continues to serve on the Citryll Board of Directors, and previously served on the boards of Antabio, Spinnovation, Audion Therapeutics and Hifibio. His therapeutic area of expertise includes rheumatoid arthritis, lupus, hidradenitis supperativa, sensorineural hearing loss, viral infections such as dengue, drug resistant bacterial infections, oncology and more. “We are honoured to welcome Helmuth to the Board of Cantoni. His impressive track record in drug discovery and development adds significant value to the progression of Cantoni’s programmes”, says Managing Director of LEH, and Director of Cantoni, Rob Mayfield. “Cantoni is a pioneer in the Nicotinamide N-methyltransferase (NNMT) space with best in class inhibitors in preclinical development for lipid disorders and cancer, originating from Leiden University. This is an exciting example of high quality science with the clear potential to become future medicines for patients in need. I am excited to join the Cantoni Board and support the team to help advance its lead asset into the clinic and beyond" says Helmuth van Es. About Cantoni: Cantoni Therapeutics B.V. is a private pharmaceutical company based in Leiden, the Netherlands that is dedicated to the development and commercialization of NNMT inhibitors. NNMT is expressed in a number of tissues including the liver and is found in other tissues such as adipocytes. NNMT is an attractive drug target for metabolic syndrome and certain cancers where it is found to be overexpressed. Elevated NNMT activity is correlated with obesity, insulin resistance and blood glucose levels as well as tumor aggressiveness and is believed to promote cancer migration, invasion, and proliferation through epigenetic changes.   Cantoni was founded in 2020 by Libertatis Ergo Holding B.V. (LEH) and scientific founders Dr Matthijs van Haren and Professor Nathaniel Martin, both scientists with an impressive track-record in discovery and optimization of small molecule drug candidates. www.cantonitx.nl   About LEH: LEH is an independent seed investor in life science and health companies, which creates, supports and invests in startup and spinout companies connected to the activities of Leiden University, many of which are located on the Leiden Bio Science Park. www.libertatisergo.com Contact: Rob Mayfield: r.h.mayfield@bb.leidenuniv.nl

Entrepreneur in Residence: Welcome Carlo Bertozzi We are thrilled to announce the addition of Carlo Bertozzi, PhD MBA, to the #Extend family as our Entrepreneur in Residence (EIR) for Extend portfolio companies. With a profound background in biochemistry and a wealth of entrepreneurial experience spanning over a decade, Carlo brings a unique blend of scientific expertise and business acumen to our initiative. About #Carlo Bertozzi, PhD MBA: Trained Biochemist: ETH Zürich, University of Queensland (Australia), University of Zurich 10+ Years of Experience: Building, Scaling, and Exiting Companies Elected Expert for InnoSuisse (Swiss Innovation Agency) Entrepreneurial Journey: Carlo has co-founded and led three successful biotech companies to date. Notably, he played a pivotal role in founding the GPCR-focused platform company G7 Therapeutics AG, later renamed Sosei Heptares Zurich in 2017. Serving as both CEO and a board member, Carlo led G7 Therapeutics AG through two multi-target collaborations with stock-listed drug development companies and a successful M&A with Sosei Heptares Ltd. Current Role: Currently, Carlo serves as the CEO and Director for InCephalo, a company dedicated to developing next-generation therapies for brain cancer patients. His leadership continues to drive innovation and make a significant impact in the biotech industry. Carlo's Perspective: "I am very excited to be part of the Extend initiative as I see a lot of untapped potential, and it allows me to Extend and apply my experience and know-how to academic projects creating tomorrow's biotech companies." Venture Support at Extend: As our Entrepreneur in Residence, Carlo will play a pivotal role in providing strategic guidance and support to our portfolio companies. His extensive experience in scaling and navigating the complexities of the biotech landscape will undoubtedly contribute to the commercial success of our initiatives. He is already following two Extend portfolio projects. Connect with Carlo Bertozzi: Let's welcome Carlo to the Extend community! Connect with him on LinkedIn to tap into his wealth of knowledge and expertise.

📖 If you want to know more about Mercia's investment into some of the UK's most innovative and ambitious businesses, then take a read of our latest blog series titled, '𝗪𝗵𝘆 𝘄𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗲𝗱' Read first hand detail and explore a bit deeper into some of Mercia's recent investments including Camena Bioscience, ImmuONE, Naitive and Laverock Therapeutics. All available ⏬ #MEIF #VCT #EIS #Biotech #Therapeutics #AI #Investment #VentureCapital #Entrepreneurship #InVitro #LifeSciences

1,000,000 hours more time for drug discovery A huge number. When you are 80 years old, your life has had 700,800 hours. How is it then possible to achieve ONE million more hours for drug discovery? My family suffers from cancer. I am afraid of cancer. I don’t want to be a victim of fate. I want to do something. Act. Develop a drug vs cancer? My life my be to short. Only 700k hours. Where is my leverage? How can I have a big impact? Biophysical tools for drug discovery. We now have 20,000 users of our tools. Assume every user works 50 weeks per week. Our tools are plug and play. Robust. Easy to learn and use. Our good user experience saves everyone at least 1 hour per week. 20,000 user x 50 weeks x 1 hour saving per week. This is 1,000,000 hours per year more time. 1,000,000 hours more for science. More than a lifetime. This is just a small part of the value we bring into life sciences. And even this has a huge impact. What we do her matter. Biophysical tools matter. Biotech matters. Your science matters. Be aware of it. You are doing great 🧬🚀🖖 #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

The #biotech entrepreneurial journey can be equal parts frustrating, exhilarating, and rewarding. In the early stages, it's essential to keep an eye on scalability and lean on partners who can help you reach your next milestone quickly and cost-effectively. Our customers attest that RoosterBio can be a powerful resource for #advancedtherapy startups by providing: ✅ Scalable and economical raw materials to take you from bench to clinic ✅ Technical guidance along the way to optimize your chance of success ✅ Expert-led services to advance your research quickly and efficiently with reduced overhead cost Learn more: https://lnkd.in/eMGMeNV3 #advancedtherapies #regenerativemedicine #gotomarket #biotechinnovation #startup

#fundingalert 💼Company: Neurenati Therapeutics  💰Funding: $1.2Million ⚡Round: Seed 👥Investors: Genson Capital Neurenati Therapeutics was founded by Nicolas Pilon, Rodolphe Soret.  The funding will be used by the company to expedite the development of NEU-001. A cutting-edge #biotechnology startup called Neurenati Therapeutics is creating a novel therapy for Hirschsprung’s illness. The company is dedicated to getting this treatment into clinical practice and has the backing of multiple #medical professionals, including #gastroenterologists and experts in clinical trials on rare disorders. Maxime Ranger Zhizi Zhao Benoit Dore Alexandre LeBeaut François Boutin, CPA Read more - https://lnkd.in/grySxF9a To share your startup story write us on - contact@startuprise.io #neurenatitherapeutics #biotechnology #meditech #news #healthtech #funding #startup